Analytic review: Interleukin-6 in surgery, trauma, and critical care: Part I: Basic science

Journal of Intensive Care Medicine

Volumn 26, Issue 1, 2011, Pages 3-12

  Jawa, Randeep S ^a   Anillo, Sergio ^b   Huntoon, Kristin ^c   Baumann, Heinz ^c   Kulaylat, Mahmoud ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

ARDS; critical care; cytokine; IL 6; interleukin; laparoscopy; sepsis; trauma

Indexed keywords

CARDIOTROPHIN 1; CARDIOTROPHIN LIKE CYTOKINE; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 11; INTERLEUKIN 27; INTERLEUKIN 31; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; NEUROPOIETIN; ONCOSTATIN M; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ALPHA CHAIN; ARTICLE; BETA CHAIN; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOREGULATION; INFLAMMATION; INTENSIVE CARE; INTRACELLULAR SIGNALING; LEUKOCYTE; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SURGICAL INJURY; TISSUE INJURY;

CRITICAL CARE; GENERAL SURGERY; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; SEPSIS; WOUNDS AND INJURIES;

EID: 79251622214     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066610395678     Document Type: Article

References (93)

1. Tilg H., Dinarello CA, Mier JW IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today. 1997 ; 18 (9). 428-432.
2. Kopf M., Baumann H., Freer G., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994 ; 368 (6469). 339-342.
3. Kushner I., Rzewnicki DL The acute phase response: general aspects. Baillieres Clin Rheumatol. 1994 ; 8 (3). 513-530.
4. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 ; 265 (3). 621-636.
5. Kushner I. C-reactive protein in rheumatology. Arthritis Rheum. 1991 ; 34 (8). 1065-1068.
6. Black S., Kushner I., Samols D. C-reactive Protein. J Biol Chem. 2004 ; 279 (47). 48487-48490.
7. Arredouani MS, Kasran A., Vanoirbeek JA, Berger FG, Baumann H., Ceuppens JL Haptoglobin dampens endotoxin-induced inflammatory effects both. in vitro. and in vivo. Immunology. 2005 ; 114 (2). 263-271.
8. Mortensen RF, Zhong W. Regulation of phagocytic leukocyte activities by C-reactive protein. J Leukoc Biol. 2000 ; 67 (4). 495-500.
9. Naka T., Nishimoto N., Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002 ; 4 (3). S233 - S242.
10. Park JY, Pillinger MH Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007 ; 65 (1). S4 - S10.
11. Cronstein BN Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007 ; 65 (1). S11 - S15.
12. Biffl WL, Moore EE, Moore FA, Carl VS, Kim FJ, Franciose RJ Interleukin-6 potentiates neutrophil priming with platelet-activating factor. Arch Surg. 1994 ; 129 (11). 1131-1136.
13. Nijsten MW, Hack CE, Helle M., ten Duis HJ, Klasen HJ, Aarden LA Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery. 1991 ; 109 (6). 761-767.
14. Scheller J., Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006 ; 195 (4). 173-183.
15. Peng J., Friese P., George JN, Dale GL, Burstein SA Alteration of platelet function in dogs mediated by interleukin-6. Blood. 1994 ; 83 (2). 398-403.
16. Grignani G., Maiolo A. Cytokines and hemostasis. Haematologica. 2000 ; 85 (9). 967-972.
17. Ahad A. Baumann H., Elias J., et al. Interleukin-6-type cytokines in diagnostics and therapeutics: roundtable discussion. Ann N Y Acad Sci. 1995 ; 762: 375-387.
18. Dimopoulou I., Tsagarakis S., Kouyialis AT, et al. Hypothalamic- pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 concentrations. Crit Care Med. 2004 ; 32 (2). 404-408.
19. Kashiwabara M., Miyashita M., Nomura T., et al. Surgical trauma-induced adrenal insufficiency is associated with postoperative inflammatory responses. J Nippon Med Sch. 2007 ; 74 (4). 274-283.
20. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998 ; 128 (2). 127-137.
21. Chesnokova V., Melmed S. Minireview: neuro-immunoendocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology. 2002 ; 143 (5). 1571-1574.
22. Wasmuth HE, Kunz D., Graf J., et al. Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-alpha. Crit Care Med. 2004 ; 32 (5). 1109-1114.
23. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003 ; 278 (16). 13740-13746.
24. Beeton CA, Chatfield D., Brooks RA, Rushton N. Circulating levels of interleukin-6 and its soluble receptor in patients with head injury and fracture. J Bone Joint Surg Br. 2004 ; 86 (6). 912-917.
25. Dekkers PE, Juffermans NP, ten Hove T., de Jonge E., van Deventer SJ, van der Poll T. Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans. J Infect Dis. 2000 ; 181 (3). 1055-1061.
26. Yahara N., Abe T., Morita K., Tangoku A., Oka M. Comparison of interleukin-6, interleukin-8, and granulocyte colony-stimulating factor production by the peritoneum in laparoscopic and open surgery. Surg Endosc. 2002 ; 16 (11). 1615-1619.
27. Ohzato H., Yoshizaki K., Nishimoto N., et al. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery. 1992 ; 111 (2). 201-209.
28. Damas P., Ledoux D., Nys M., et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992 ; 215 (4). 356-362.
29. Hack CE, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989 ; 74 (5). 1704-1710.
30. Heinrich PC, Behrmann I., Müller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/ STAT pathway. Biochem J. 1998 ; 334 (2). 297-314.
31. Auernhammer CJ, Melmed S. Leukemia-inhibitory factorneuroimmune modulator of endocrine function. Endocr Rev. 2000 ; 21 (3). 313-345.
32. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells. 2003 ; 21 (1). 5-14.
33. Ranieri VM, Suter PM, Tortorella C., et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999 ; 282 (1). 54-61.
34. Pan W., Yu C., Hsuchou H., Zhang Y., Kastin AJ Neuroinflammation facilitates LIF entry into brain: role of TNF. Am J Physiol Cell Physiol. 2008 ; 294 (6). C1436-1442.
35. Wahl AF, Wallace PM Oncostatin M in the anti-inflammatory response. Rev Physiol Biochem Pharmacol. 2003 ; 149: 39-52.
36. Wallace P., MacMaster J., Rillema J., et al. In vivo properties of Oncostatin M. Ann N Y Acad Sci. 1995 ; 762 (1). 42-54.
37. Gómez-Lechón MJ Oncostatin M.: signal transduction and biological activity. Life Sci. 1999 ; 65 (20). 2019-2030.
38. Pignatti P., Ciapponi L., Galle P., et al. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clin Exp Immunol. 2003 ; 131 (2). 355-363.
39. Latchman DS Cardiotrophin-1: a novel cytokine and its effects in the heart and other tissues. Pharmacol Ther. 2000 ; 85 (1). 29-37.
40. Huising MO, Kruiswijk CP, Flik G. Phylogeny and evolution of class-I helical cytokines. J Endocrinol. 2006 ; 189 (1). 1-25.
41. Hamanaka I., Saito Y., Nishikimi T., et al. Effects of cardiotrophin-1 on hemodynamics and endoc1rine function of the heart. Am J Physiol Heart Circ Physiol. 2000 ; 279 (1). H388 - H396.
42. Pulido EJ, Shames BD, Pennica D., et al. Cardiotrophin-1 attenuates endotoxin-induced acute lung injury. J Surg Res. 1999 ; 84 (2). 240-246.
43. Derouet D., Rousseau F., Alfonsi F., et al. Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc Natl Acad Sci USA. 2004 ; 101 (14). 4827-4832.
44. Guillet C., Fourcin M., Chevalier S., Pouplard A., Gascan H. ELISA detection of circulating levels of LIF, OSM, and CNTF in septic shock. Ann N Y Acad Sci. 1995 ; 762: 407-409.
45. Schinkel C., Wick M., Muhr G., Köller M. Analysis of systemic interleukin-11 after major trauma. Shock. 2005 ; 23 (1). 30-34.
46. Heizmann O., Koeller M., Muhr G., Oertli D., Schinkel C. Th1- and Th2-type cytokines in plasma after major trauma. J Trauma. 2008 ; 65 (6). 1374-1378.
47. Opal S., Keith J. Jr, Jhung J., et al. Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis. J Infect Dis. 2003 ; 187 (1). 70-76.
48. Kastelein RA, Hunter CA, Cua DJ Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007 ; 25: 221-242.
49. Villarino AV, Hunter CA Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res Ther. 2004 ; 6 (5). 225-233.
50. Takaoka A., Arai I., Sugimoto M., Yamaguchi A., Tanaka M., Nakaike S. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol. 2005 ; 516 (2). 180-181.
51. Dillon SR, Sprecher C., Hammond A., et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004 ; 5 (7). 752-60. Erratum in Nat Immunol. 2005 ; 6 (1). 114.
52. Jawa R., Chattopadhyay S., Tracy E., et al. Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages. J Interferon Cytokine Res. 2008 ; 28 (4). 207-219.
53. Ip WK, Wong CK, Li ML, et al. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology. 2007 ; 122 (4). 532-541.
54. Perrigoue JG, Li J., Zaph C., et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med. 2007 ; 204 (3). 481-487.
55. Marsik C., Halama T., Cardona F., Schlifke I., Mittermayer F., Jilma B. Endotoxemia enhances expression of the signaling receptor (GP130) on protein and molecular level. Clin Immunol. 2005 ; 114 (3). 293-298.
56. Yu X., Kennedy RH, Liu SJ JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem. 2002 ; 278 (18). 16304-16309.
57. Petersen AM, Pedersen BK The anti-inflammatory effect of exercise. J Appl Physiol. 2005 ; 98 (4). 1154-1162.
58. May L., Ndubisi M., Patel K., Garcia D. Interleukin-6 chaperones in blood. Ann N Y Acad Sci. 1995 ; 762: 120-128.
59. Sutherland AM, Walley KR, Manocha S., Russell JA The association of interleukin-6 haplotype clades with mortality in critically ill adults. Arch Intern Med. 2005 ; 165 (1). 75-82.
60. Annane D., Sébille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 ; 288 (7). 862-871. Erratum in JAMA. 2008 ; 300 (14). 1652.
61. Sochorova K., Horvath R., Rozkova D., et al. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen presenting cells from patients with X-linked agammaglobulinemia. Blood. 2007 ; 109 (6). 2553-2556.
62. Krishnan J., Selvarajoo K., Tsuchiya M., Lee G., Choi S. Toll-like receptor signal transduction. Exp Mol Med. 2007 ; 39 (4). 421-438.
63. Schilling D., Thomas K., Nixdorff K., Vogel SN, Fenton MJ Toll-like receptor 4 and Toll-IL-1 receptor domain-containing adapter protein (TIRAP)/myeloid differentiation protein 88 adapter-like (Mal) contribute to maximal IL-6 expression in macrophages. J Immunol. 2002 ; 169 (10). 5874-5880.
64. Dissanayake S., Amith RS, Shahin A. Taenia crassiceps carbohydrates stimulate IL-6 expression in naïve murine macrophages via Toll-like receptors (TLRs). Mol Immunol. 2004 ; 41 (4). 391-398.
65. Ndubuisi MI, Patel K., Rayanade RJ, Mittelman A., May LT, Sehgal PB Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. J Immunol. 1998 ; 160 (1). 494-501.
66. Bravo J., Heath JK Receptor recognition by gp130 cytokines. EMBO J. 2000 ; 19 (11). 2399-2411.
67. Kishimoto T. IL-6: from laboratory to bedside. Clin Rev Allergy Immunol. 2005 ; 28 (3). 177-186.
68. http://www.wikipedia.com. Accessed October 14, 2009.
69. Zvonic S., Baugh JEJr, Arbour-Reily P., Mynatt RL, Stephens JM Cross-talk among gp130 cytokines in adipocytes. J Biol Chem. 2005 ; 280 (40). 33856-33863.
70. Heinrich PC, Behrmann I., Haan S., Hermanns HM, Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem J. 2003 ; 374 (pt 1). 1-20.
71. Pathan N., Williams EJ, Oragui EE, Stephens AC, Levin M. Changes in the interleukin-6/soluble interleukin-6 receptor axis in meningococcal septic shock. Crit Care Med. 2005 ; 33 (8). 1839-1844.
72. John S. Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol. 2003 ; 50 (3). 603-611.
73. Rose-John S., Scheller J., Elson G., Jones SA Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006 ; 80 (2). 227-236.
74. Fitzgerald K., O'Neill L., Gearing A., Callard R. Interleukin-6. The cytokine factsbook. London, UK: Academic Press ; 2001: 69-72.
75. Walev I., Vollmer P., Palmer M., Bhakdi S., Rose-John S. Pore-forming toxins trigger shedding of receptors for interleukin-6 and lipopolysaccharide. Proc Natl Acad Sci USA. 1996 ; 93 (15). 7882-7887.
76. Taga T., Hibi M., Hirata Y., et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989 ; 58 (3). 573-581.
77. Nakajima T., Yamamoto S., Cheng M., et al. Soluble interleukin-6 receptor is released from receptor-bearing cell lines in vitro. Jpn J Cancer Res. 1992 ; 83 (4). 373-378.
78. Jones SA, Horiuchi S., Topley N., Yamamoto N., Fuller GM The soluble interleukin-6 receptor: mechanisms of production and implications in disease. FASEB J. 2001 ; 15 (1). 43-58.
79. Campo S., Serlupi-Crescenzi O., Arseni B., et al. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma. Cytokine. 2005 ; 31 (5). 368-374.
80. Acalovschi D., Wiest T., Hartmann M., et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke. 2003 ; 34 (8). 1864-1869.
81. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/ gp130 complex. Science. 2003 ; 300 (5628). 2101-2104. Erratum in Science. 2003 ; 301: 918..
82. Diveu C., Lak-Hal AH, Froger J., et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw. 2004 ; 15 (4). 291-302.
83. http://www.ncbi.nlm.nih.gov/gene. Accessed September 14, 2010.
84. Corbi P., Rahmati M., Delwail A., et al. Circulating soluble gp130, soluble IL-6R, and IL-6 in patients undergoing cardiac surgery, with or without extracorporeal circulation. Eur J Cardiothorac Surg. 2000 ; 18 (1). 98-103.
85. Andrejko KM, Raj NR, Kim PK, Cereda M., Deutschman CS IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock. 2008 ; 29 (4). 490-496.
86. Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000 ; 19 (21). 2548-2556.
87. Fielding CA, McLoughlin RM, McLeod L., et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol. 2008 ; 181 (3). 2189-2195.
88. Sehgal PB Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol. 2008 ; 19 (4). 329-340.
89. Sehgal PB Plasma membrane rafts and chaperones in cytokine/ STAT signaling. Acta Biochim Pol. 2003 ; 50 (3). 583-594.
90. Shah M., Patel K., Fried VA, Sehgal PB Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signaling during fever. J Biol Chem. 2002 ; 277 (47). 45662-45669.
91. Kushner I., Rzewnicki D., Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006 ; 119 (2). 166.e17-166.e28.
92. Billiar TR, Curran RD, Williams DL, Kispert PH Liver nonparenchymal cells are stimulated to provide interleukin-6 for induction of the hepatic acute-phase response in endotoxemia but not in remote localized inflammation. Arch Surg. 1992 ; 127 (1). 31-36.
93. Derhaschnig U., Bergmair D., Marsik C., Schlifke I., Wijdenes J., Jilma B. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med. 2004 ; 32 (5). 1136-1140. Erratum in Crit Care Med. 2004 ; 32 (8). 1813.